AI strain-design & engineering platforms

01Overview and value chain#

Markers EC: AI-native protein/strain design & autonomous lab platforms | OECD: Bioeconomy policy & governance | Regulator: none dedicated

AI strain-design and engineering platforms are a B2B services category providing AI-native software that designs microbial strains, proteins and antibodies computationally, distinct from the traditional wet-lab strain-engineering contract-research-organization model. Ginkgo Bioworks launched Ginkgo Cloud Lab in 2026, a browser-based interface letting researchers run biological protocols on its autonomous lab infrastructure directly, transitioning benchwork to cloud-accessible automation. Absci runs Origin-1, a generative AI platform for de novo antibody design against novel epitopes, and collaborated with Twist Bioscience to combine its generative-AI drug-creation platform with DNA synthesis to accelerate novel therapeutic antibody design. Cradle runs an AI protein-design platform, with its CRADLE-1 model performing automated lead optimization of proteins as a next step beyond de novo generation. LabGenius operates a closed-loop discovery platform built around its EVA platform, unlocking high-performing molecules with non-intuitive designs across binder, linker and half-life-extension-domain building blocks. EvolutionaryScale develops the ESM (Evolutionary Scale Modeling) family of protein language models, open-sourced and widely adopted, with thousands of GitHub stars reflecting broad developer and research uptake.

The key directions of AI strain-design and engineering platforms are:

Generative protein design models: AI models that generate novel protein and antibody structures de novo against specified targets or epitopes, rather than screening natural variants.
Autonomous lab infrastructure: cloud-accessible robotic lab infrastructure letting researchers run biological protocols remotely through a software interface.
Closed-loop design-build-test-learn platforms: integrated platforms where AI-generated designs are automatically built, tested and the results fed back to improve the next design cycle.
Protein language models: large-scale models trained on protein sequence/structure data, providing a foundational layer for downstream generative design and lead-optimization tools.

Sectoral value chain#

[Target/epitope specification] ──> [AI-generated candidate design] ──> [Automated build/synthesis]
                                                                        │
                                                              (Closed-loop testing)
                                                                        │
              [Lead candidate selection] <──── [Data feedback to model] <─── [Functional/binding assay]

Fig. 1— Sectoral value chain

Value chain levels#

Level	Description	Key inputs/outputs
Target/epitope specification	Defining the target protein, epitope or functional specification the AI design process must satisfy.	In: Research/therapeutic objective. Out: Target specification.
AI-generated candidate design	Generative or protein-language models produce novel candidate protein, antibody or strain designs against the specification.	In: Target specification. Out: Candidate design set.
Automated build/synthesis	Candidate designs are synthesized or constructed, often via automated or robotic lab infrastructure.	In: Candidate design set. Out: Physical candidate constructs.
Functional/binding assay	Physical candidates are tested for the target function or binding property in automated assays.	In: Physical candidate constructs. Out: Assay results.
Data feedback to model	Assay results are fed back into the AI model to improve subsequent design rounds.	In: Assay results. Out: Updated model/training data.
Lead candidate selection	The best-performing candidates from the closed-loop cycle are selected as leads for further development.	In: Updated model/training data, assay results. Out: Selected lead candidates.

Table 1— Value chain levels

Cross-cutting technologies of the sector:

Generative protein design models: AI models generating novel protein and antibody structures de novo against a specified target or epitope.
Autonomous lab infrastructure: cloud-accessible robotic lab infrastructure letting researchers run biological protocols remotely through a software interface.
Closed-loop design-build-test-learn: integrated platforms where AI-generated designs are automatically built, tested and the results fed back to improve subsequent design cycles.

02US#

The United States hosts the leading AI-native strain, protein and antibody design platforms, spanning cloud lab infrastructure, generative drug design and open-source protein language models.

Ginkgo Bioworks’ Cloud Lab, Absci’s Origin-1 antibody design, EvolutionaryScale’s ESM models#

Ginkgo Bioworks: launched Ginkgo Cloud Lab in 2026, a browser-based interface letting researchers run biological protocols on its autonomous lab infrastructure directly, transitioning benchwork to cloud-accessible automation.
Absci: runs Origin-1, a generative AI platform for de novo antibody design against novel epitopes, and collaborated with Twist Bioscience to combine generative-AI drug creation with DNA synthesis.
EvolutionaryScale: develops the ESM (Evolutionary Scale Modeling) family of protein language models, open-sourced and widely adopted across the research community.

03CN#

China is covered qualitatively rather than through a live-screened Chinese vendor: candidate Chinese AI strain-design platforms searched during this screen returned no confirming 2026 source specific to this service category.

No China-headquartered vendor confirmed in this screen#

Search outcome: two candidate Chinese firms were searched during this screen and neither returned a confirming live 2026 source for this specific service category.
Market presence: China has substantial synthetic-biology R&D investment, but no China-headquartered AI-native strain/protein-design platform vendor was independently confirmed in this screen.

04EU#

Europe hosts specialist AI protein-engineering platforms in the Netherlands and UK, applying generative and closed-loop design methods to lead optimization and novel molecule design.

Cradle’s automated lead optimization, LabGenius’ closed-loop discovery platform#

Cradle: headquartered in the Netherlands, runs an AI protein-design platform, with its CRADLE-1 model performing automated lead optimization of proteins as a next step beyond de novo generation.
LabGenius: headquartered in the UK, operates a closed-loop discovery platform built around its EVA platform, unlocking high-performing molecules with non-intuitive designs.

05Leading companies and research institutes#

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
Ginkgo Bioworks	🇺🇸 USA	Ginkgo Cloud Lab	Browser-based autonomous lab access	commercial
Absci	🇺🇸 USA	Origin-1 generative antibody design	De novo design against novel epitopes	commercial
Cradle	🇳🇱 Netherlands	CRADLE-1 protein design	Automated lead optimization	commercial
LabGenius	🇬🇧 UK	EVA closed-loop discovery platform	Non-intuitive high-performing designs	commercial
EvolutionaryScale	🇺🇸 USA	ESM protein language models	Open-source, broad developer adoption	commercial

Table 2— Leading companies and research institutes

06Tech stack and innovations#

The AI strain-design and engineering platform technology stack combines generative modeling, protein language models and closed-loop automation to compress design cycles:

Generative de novo protein/antibody design:
- Absci’s Origin-1 generates novel antibody candidates de novo against specified novel epitopes, moving beyond screening natural antibody libraries.
Automated lead optimization beyond de novo generation:
- Cradle’s CRADLE-1 model performs automated lead optimization as a distinct next step after de novo protein generation, refining candidates toward manufacturability and performance.
Cloud-accessible autonomous lab infrastructure:
- Ginkgo Bioworks’ Cloud Lab lets researchers transition benchwork directly to autonomous lab infrastructure through a browser interface, removing physical-lab-access as a bottleneck.

07Value chains and production pipelines#

Industrial pipeline for an AI-driven protein/strain design cycle#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Target/epitope           │ ───> │ 2. AI-generated             │
│    specification                 │      │    candidate design               │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Functional/binding       │ <─── │ 3. Automated                 │
│    assay                         │      │    build/synthesis                │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Data feedback             │ ───> │ 6. Lead candidate            │
│    to model                      │      │    selection                      │
└───────────────────────────┘      └───────────────────────────┘

Fig. 2— Industrial pipeline for an AI-driven protein/strain design cycle

Stage 1: Target/epitope specification

The target protein, epitope or functional specification the AI design process must satisfy is defined.

Stage 2: AI-generated candidate design

Generative or protein-language models produce novel candidate protein, antibody or strain designs against the specification.

Stage 3: Automated build/synthesis

Candidate designs are synthesized or constructed, often via automated or robotic lab infrastructure.

Stage 4: Functional/binding assay

Physical candidates are tested for the target function or binding property in automated assays.

Stage 5: Data feedback to model

Assay results are fed back into the AI model to improve subsequent design rounds.

Stage 6: Lead candidate selection

The best-performing candidates from the closed-loop cycle are selected as leads for further development.

Supplier	Region & tags
Ginkgo Bioworks	US
Absci	US
Cradle	EU
LabGenius	EU
EvolutionaryScale	US

AI Recommendation

Key directions:

Generative protein design models — AI models that generate novel protein and antibody structures de novo against specified targets or epitopes, rather than screening natural variants.
Autonomous lab infrastructure — cloud-accessible robotic lab infrastructure letting researchers run biological protocols remotely through a software interface.
Closed-loop design-build-test-learn platforms — integrated platforms where AI-generated designs are automatically built, tested and the results fed back to improve the next design cycle.
Protein language models — large-scale models trained on protein sequence/structure data, providing a foundational layer for downstream generative design and lead-optimization tools.

Regulatory:

No dedicated regulator governs the design-platform layer itself; downstream products (therapeutics, industrial enzymes, food ingredients) fall under existing FDA/EMA/USDA regimes depending on end use, but the AI design software is not separately regulated.
The category’s risk framing is technology-maturity risk rather than compliance risk — several of these platforms (EvolutionaryScale, Cradle) are recent entrants building on protein language models that only became broadly usable in the past few years.

Companies not in table: two candidate Chinese firms were searched for this screen and neither returned a confirming live 2026 source, so China stays qualitative rather than tabled from general knowledge.

Category boundary: distinct from strain engineering (synbio CRO) — that category is the traditional wet-lab contract-research-organization service model (directed evolution, computational protein design delivered as a service); this category is the AI-native software/platform layer itself, whether sold as a product, a cloud service, or embedded in a company’s own drug/strain pipeline.

Processing note: China has substantial synthetic-biology R&D investment, but no China-headquartered AI-native strain/protein-design platform vendor was independently confirmed in this screen — a gap likely reflecting how recent and US/EU-concentrated this specific software layer is, rather than a structural absence of Chinese synthetic-biology capability.

Buyer relevance: a biopharma or industrial-biotech team choosing among these vendors is typically weighing how far along the design-to-lab pipeline a platform reaches — from a pure design/modeling layer (EvolutionaryScale) through generative therapeutic design (Absci, LabGenius, Cradle) to a fully integrated cloud-accessible physical lab (Ginkgo Bioworks) — rather than choosing on model accuracy alone.